|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
BEFREE |
Approximately 82% electrophoretically homogeneous SCZ IgGs purified using several affinity sorbents including Sepharose with immobilized MBP hydrolyze specifically only MBP but not many other tested proteins.
|
30112774 |
2019 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis was used to compare protein levels of myelin basic protein, neurofilament heavy, autophagosome marker LC3, and microtubule marker α-tubulin in post-mortem human CB, CC, and AF in schizophrenia subjects (SZ) and matched normal controls (NC).
|
30735241 |
2019 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
Myelin basic protein (MBP) is a major component of the myelin sheath of CNS neurons and may play a central role in demyelinating diseases such as MS.
|
28413712 |
2017 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
MBP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.
|
28694532 |
2017 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
Myelin basic protein and 2', 3'-cyclic nucleotide 3'-phosphodiesterase were also significantly decreased in the mouse model of SZ.
|
24788877 |
2014 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
RGD |
Myelination deficit in a phencyclidine-induced neurodevelopmental model of schizophrenia.
|
22750584 |
2012 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
Reduced MBP mRNA in schizophrenia replicates findings in other brain regions and is consistent with oligodendrocyte involvement in the disorder.
|
22675524 |
2012 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
Reduced MBP mRNA in schizophrenia replicates findings in other brain regions and is consistent with oligodendrocyte involvement in the disorder.
|
22675524 |
2012 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that altered expression levels of hnRNP C in the brain of patients with schizophrenia could be involved in the pathophysiology of this disease through alteration of the QKI isoform and myelin basic protein expression.
|
21684615 |
2011 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
LHGDN |
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.
|
19034380 |
2009 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
In addition we performed an expression analysis of golli-MBP mRNA in post-mortem dorsolateral prefrontal cortex samples of schizophrenia patients, and matched controls.
|
19154657 |
2009 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
LHGDN |
These included alterations previously implicated in schizophrenia, such as oligodendrocyte-related proteins (myelin basic protein and transferrin), as well as malate dehydrogenase, aconitase, ATP synthase subunits and cytoskeleton-related proteins.
|
19110265 |
2009 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
In addition we performed an expression analysis of golli-MBP mRNA in post-mortem dorsolateral prefrontal cortex samples of schizophrenia patients, and matched controls.
|
19154657 |
2009 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
Alterations of the balance between MBP-specific proliferation and PCD are present in demyelinating diseases and could play a major role in the pathogenesis of these diseases.
|
18930441 |
2008 |
|
Schizophrenia
|
0.580 |
Biomarker
|
disease |
PSYGENET |
Correlation and factor analyses revealed that mRNA levels for genes that did exhibit differential expression in schizophrenia (MAG, CNP, SOX10, CLDN11, and PMP2), as opposed to those that did not (MOBP and MBP), loaded on separate factors.
|
16213148 |
2006 |
|
Schizophrenia
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
Correlation and factor analyses revealed that mRNA levels for genes that did exhibit differential expression in schizophrenia (MAG, CNP, SOX10, CLDN11, and PMP2), as opposed to those that did not (MOBP and MBP), loaded on separate factors.
|
16213148 |
2006 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
Myelin basic protein (MBP) is required for normal myelin compaction and is implicated in both experimental and human demyelinating diseases.
|
14614079 |
2003 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
RGD |
Insertion of a retrotransposon in Mbp disrupts mRNA splicing and myelination in a new mutant rat.
|
10212300 |
1999 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
These findings are also evidence for limited usage of V-region Ig genes in the immune response of humans to MBP and the possible importance of an Id network for MBP in demyelinating disease.
|
9484364 |
1998 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
Myelin basic protein in experimental allergic encephalomyelitis is not affected at the posttranslational level: implications for demyelinating disease.
|
8739153 |
1996 |
|
Demyelinating Diseases
|
0.580 |
GeneticVariation
|
group |
BEFREE |
Recombinant vaccinia viruses encoding an encephalitogenic portion of myelin basic protein (MBP) were evaluated in an animal model for human demyelinating disease, experimental allergic encephalomyelitis (EAE).
|
8632058 |
1996 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
BEFREE |
Experimental allergic encephalomyelitis (EAE) is a T cell mediated model of demyelinating disease that develops as a result of an autoimmune response to the myelin structural antigen, myelin basic protein (MBP).
|
1718484 |
1991 |
|
Demyelinating Diseases
|
0.580 |
Biomarker
|
group |
CTD_human |
High-dose methotrexate-induced neurotoxicity associated with elevation of CSF myelin basic protein.
|
2580064 |
1985 |
|
Neuromyelitis Optica
|
0.330 |
Biomarker
|
disease |
BEFREE |
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder.
|
29519720 |
2018 |
|
Neuromyelitis Optica
|
0.330 |
Biomarker
|
disease |
BEFREE |
We measured CSF cell counts; concentrations of proteins, glucose, interleukin (IL)-6, IL-10, soluble IL-2 receptor (sIL-2R), and myelin basic protein; and IgG index in patients with multiple sclerosis (MS, n = 64), neuromyelitis optica spectrum disorder (NMOSD, n = 35), tumefactive demyelinating lesion (TDL, n = 17), CNS lymphoma ( n = 12), or glioma ( n = 10).
|
28657431 |
2018 |